Core Viewpoint - The company reported a revenue of 934 million yuan for the year 2025, marking a year-on-year increase of 25.64%, while the net profit attributable to the parent company was a loss of 336 million yuan, an improvement from a loss of 510 million yuan in the previous year [1] Revenue Growth - The increase in revenue is attributed to the company's active market expansion, with sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shuaili) steadily rising compared to the previous year [1] - The company also launched Ustekinumab injection (STARJEMZA) in the United States during the reporting period, contributing to growth in both licensing income and sales revenue [1]